{"id":19219,"date":"2023-04-27T20:51:00","date_gmt":"2023-04-27T12:51:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19219"},"modified":"2024-12-21T20:53:57","modified_gmt":"2024-12-21T12:53:57","slug":"microport-scientific-corp-reports-8-revenue-growth-and-increased-rd-investment-in-2022","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19219","title":{"rendered":"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022"},"content":{"rendered":"\n

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853<\/a>) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a loss of USD 351 million in 2021, the company’s research and development (R&D) costs rose by 41.0% YOY to USD 419.8 million, indicating a significant investment in ongoing and new R&D projects.<\/p>\n\n\n\n

Business Segment Growth and Performance<\/strong>
Neurovascular devices, endovascular and peripheral vascular devices, heart valves, and surgical robot businesses were highlighted as key growth drivers with YOY expansions of 43.0%, 31.0%, 25.0%, and 904.8% respectively. Orthopedics, cardiovascular rhythm management (CRM), and cardiovascular device businesses also saw stable revenue growth of 9.5%, 3.5%, and 2.3% YOY respectively.<\/p>\n\n\n\n

Geographical Revenue Distribution<\/strong>
MicroPort\u2019s revenues were geographically distributed as follows: China 48.2%; North America 11.5%; Europe 29.4%; Asia excluding China 7.6%; and South America 1.4%. Ex-China international markets contributed USD 435.2 million in revenues, marking a 10.1% YOY increase.<\/p>\n\n\n\n

Key Business Highlights<\/strong>
Chairman Zhang Chaohua noted several key business highlights for the year, including a 60% YOY growth in international markets for the cardiovascular device (CVD) business, driven by Europe, the Middle East and Africa (EMEA), and Latin America. The CVD business also secured success in China by winning bid spots for three products in the national volume-based procurement (VBP) program for coronary stents, with two products experiencing price increases. The company also achieved product approvals for a guide wire and filed for microcatheter, guiding catheter, and anchor balloon products.<\/p>\n\n\n\n

The orthopedics business saw a global operating revenue increase of 9.5% YOY, attributable to a solid overseas performance. The CRM business recorded a 3.5% growth in global operating revenues, despite overseas inflation and domestic Covid outbreaks. The endovascular and peripheral vascular devices business experienced a 31% YOY growth due to innovative products. Lastly, the neurovascular devices business saw particularly strong growth of 43% in the domestic market, positioning MicroPort as the leading company in terms of market share among domestic manufacturers.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[69,27,982,192],"class_list":["post-19219","post","type-post","status-publish","format-standard","hentry","category-company","tag-cvd","tag-finanical-reports","tag-hkg-0853","tag-microport-scientific"],"yoast_head":"\nMicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a loss of USD 351 million in 2021, the company's research and development (R&D) costs rose by 41.0% YOY to USD 419.8 million, indicating a significant investment in ongoing and new R&D projects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19219\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19219\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T12:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-21T12:53:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19219#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19219\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022\",\"datePublished\":\"2023-04-27T12:51:00+00:00\",\"dateModified\":\"2024-12-21T12:53:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19219\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CVD\",\"Finanical Reports\",\"HKG: 0853\",\"MicroPort Scientific\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19219#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19219\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19219\",\"name\":\"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-27T12:51:00+00:00\",\"dateModified\":\"2024-12-21T12:53:57+00:00\",\"description\":\"Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a loss of USD 351 million in 2021, the company's research and development (R&D) costs rose by 41.0% YOY to USD 419.8 million, indicating a significant investment in ongoing and new R&D projects.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19219#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19219\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19219#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022 - Insight, China's Pharmaceutical Industry","description":"Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a loss of USD 351 million in 2021, the company's research and development (R&D) costs rose by 41.0% YOY to USD 419.8 million, indicating a significant investment in ongoing and new R&D projects.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19219","og_locale":"en_US","og_type":"article","og_title":"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19219","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-27T12:51:00+00:00","article_modified_time":"2024-12-21T12:53:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19219#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19219"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022","datePublished":"2023-04-27T12:51:00+00:00","dateModified":"2024-12-21T12:53:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19219"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CVD","Finanical Reports","HKG: 0853","MicroPort Scientific"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19219#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19219","url":"https:\/\/flcube.com\/?p=19219","name":"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-27T12:51:00+00:00","dateModified":"2024-12-21T12:53:57+00:00","description":"Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial report, showing an 8% year-on-year (YOY) increase in revenue to USD 840.8 million, which represents a 15.6% increase when excluding foreign exchange impact. Despite reporting a net loss of USD 588 million, up from a loss of USD 351 million in 2021, the company's research and development (R&D) costs rose by 41.0% YOY to USD 419.8 million, indicating a significant investment in ongoing and new R&D projects.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19219#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19219"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19219#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19219"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19219\/revisions"}],"predecessor-version":[{"id":19220,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19219\/revisions\/19220"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}